The Switch
The math looked simple. A competing referral capture vendor offered Jane Pauley Community Health Center (JPCHC) a lower rate. For an FQHC managing tight margins in Indianapolis, that’s a hard number to ignore.
JPCHC’s previous pharmacy director made the call. They moved the referral capture program away from par8o.
“Honestly, it was due to the lower rate they were offering.”
— Christy Davis, PharmD, Director of Pharmacy Operations, JPCHC
No drama. No dissatisfaction. Just a spreadsheet that said one number was smaller than the other.
The Other Side
The rate was lower. Everything else was harder.
Operationally, the new vendor required JPCHC’s team to download encounter files from a secure drive and upload them manually into their EMR. It wasn’t necessarily the hours—it was one more process layered onto a pharmacy team that was already stretched, pulling attention from patient care to data entry every week.
But the operational burden wasn’t what brought them back. The audit was.
The Audit
When Dr. Christy Davis came on board as Director of Pharmacy Operations, she inherited the new vendor relationship. During routine internal audit reviews, her team pulled a sample of referral claims to verify documentation.
The sample was small. The pattern was unmistakable.
Of the claims reviewed, four or five lacked appropriate referral documentation. Every single one had been captured by the competing vendor. Not some of them. All of them.
“Ultimately it came down to trust. During our internal audit reviews, every claim that we had an issue finding appropriate documentation as to why it passed as a referral was captured by [the other vendor]. At that point, the liability risk was not worth the lower rate.”
— Christy Davis, PharmD, Director of Pharmacy Operations, JPCHC
Dr. Davis is clear: the audit findings were the last straw, not the only issue. Other concerns had been accumulating. But when every problem in a sample traces to one vendor, you don’t need a larger dataset. The pattern tells you everything.
Context makes it sharper. Each advanced referral claim is worth an average of $387 in 340B savings. Even a handful of undocumented claims represents real dollars—and the compliance exposure scales with every claim you can’t defend.
*NuvemRx national network performance data, 800+ covered entities
That’s not a preference. That’s an audit finding. And in a 340B program, audit findings have consequences that make a lower rate look like a rounding error.
The Return
Dr. Davis made the call to bring JPCHC back to par8o, which was then acquired by NuvemRx.
The track record Dr. Davis was buying back into: 30+ HRSA audits across the combined NuvemRx and par8o networks, zero confirmed findings. That’s not a marketing claim. It’s a compliance record built over more than a decade of specialization in 340B referral capture.
*NuvemRx national network performance data, 800+ covered entities
Dr. Davis wasn’t making this decision alone. More than 500 covered entities trust NuReferrals powered by par8o for referral capture—the largest dedicated referral capture network in 340B.
The relationship goes deeper than claims processing. Dr. Davis’s team meets regularly with NuvemRx to review their specific program. When they hired an in-house referral specialist to help capture claims and manage costs, the NuReferrals team adapted to support the new workflow without friction. That’s the difference between a rate and a relationship.
What the Numbers Show
Since returning to NuReferrals, powered by par8o, JPCHC referral capture program hasn’t just recovered. It’s grown.
Over the past 15 months, they've captured $2.1 million in net 340B savings for JPCHC—before fees. In 2025 alone, the program generated $1.77 million, with monthly savings nearly doubling from $108,000 in January to a peak of $203,000 in December—87% growth over the course of the year.
*NuvemRx/par8o internal data, JPCHC monthly volume report (Jan 2025–Mar 2026)
Two-thirds of that value comes from specialty referrals. 67% of all captured savings are specialty claims—led by Humira and biosimilars—the high-value prescriptions that a referral capture program exists to find.
*NuvemRx/par8o internal data, JPCHC monthly volume report (April 2026)
Those aren’t scripts JPCHC’s team would have caught on their own. Specialty referrals flow through external providers, across pharmacy networks, through documentation chains that require someone watching the full picture. That’s what NuReferrals does.
What’s Different Now
Since Dr. Davis brought JPCHC back, par8o has become NuReferrals powered by par8o—now part of NuvemRx’s Unified Pharmacy Care Model. The referral capture program they trusted enough to return to now connects directly to NuvemRx’s TPA data.
The referral capture engine doesn’t operate in a silo anymore. It sees scripts across the full pharmacy network—Walgreens, CVS, independent, and specialty pharmacies—with up to 85% of the referral and eligibility process automated by AI.
That visibility matters because fewer than one-third of covered entities capture specialty referrals at all. Two-thirds of programs are leaving specialty referral dollars on the table. JPCHC’s $1.4 million in specialty savings over 15 months is proof of what’s possible when you’re not.
*NuvemRx internal data, specialty total from JPCHC volume report
Dr. Davis came back for trust and compliance. What she has now is trust, compliance, and visibility into scripts that were previously locked away.
What She Tells Colleagues
Asked what she’d say to a colleague considering a switch away from par8o and NuvemRx, Dr. Davis doesn’t hedge:
“Par8o+NuvemRx has an exceptional track record with HRSA audits. The staff is wonderful. I’ve never felt rushed or unimportant. They are always extremely responsive and willing to work with us on whatever our needs are. [In the end,] the liability risk was not worth the lower rate.”
— Christy Davis, PharmD, Director of Pharmacy Operations, JPCHC
The Bigger Math
JPCHC’s story is a lesson in what “cheaper” actually costs. A lower rate on referral capture means nothing if the claims don’t survive your own internal audit. And claims that don’t survive internal audit won’t survive an HRSA review.
The market is making this calculus sharper. Advanced referral margins declined 26.7% year over year in Q1 2026. When every compliant claim is worth less than it was a year ago, you cannot afford to lose claims to bad documentation. The margin for error—literally—is shrinking.
*NuvemRx national network performance data, 800+ covered entities
JPCHC’s own numbers show the other side of that equation. Despite market-wide margin compression, their program grew 87% in 2025 and generated $2.1 million in net savings over 15 months. That’s what happens when the vendor behind your referral capture is finding claims that actually hold up.
*NuvemRx internal data, JPCHC report
They’re not alone. A comparable NuReferrals referral capture client—a New England health center—achieved 100%+ program growth within six months of implementation, with 100% of specialty scripts captured and a clean audit.
*NuvemRx internal performance data
Every compliant referral claim captured—every specialty script identified across the full pharmacy network—is 340B savings that flows back into the community JPCHC serves. More staff, more services, more access for patients in Indianapolis who need it most.
Every non-compliant claim is a liability that threatens the program those patients depend on.
The math was never about the rate. It was about what the rate was buying.
The rate isn’t the math that matters.
NuReferrals powered by par8o—now part of NuvemRx’s Unified Pharmacy Care Model—has helped FQHCs, Ryan White clinics, and safety-net health systems capture specialty referrals compliantly, with zero reported HRSA audit findings and visibility across the full pharmacy network. If you’re evaluating referral capture vendors, or wondering whether your current partner’s claims would survive your own internal audit, let’s look at your numbers.